Conformation of DNA GG intrastrand cross-link of antitumor oxaliplatin and its enantiomeric analog.
Downstream processes that discriminate between DNA adducts of a third generation platinum antitumor drug oxaliplatin and conventional cisplatin are believed to be responsible for the differences in their biological effects. These different biological effects are explained by the ability of oxaliplatin to form DNA adducts more efficient in their biological effects. In this work conformation, recognition by HMG domain protein and DNA polymerization across the major 1,2-GG intrastrand cross-link formed by cisplatin and oxaliplatin in three sequence contexts were compared with the aid of biophysical and biochemical methods. The following major differences in the properties of the cross-links of oxaliplatin and cisplatin were found: i), the formation of the cross-link by oxaliplatin is more deleterious energetically in all three sequence contexts; ii), the cross-link of oxaliplatin bends DNA slightly but systematically less in all sequence contexts tested; iii), the affinity of HMG domain protein to the cross-link of oxaliplatin is considerably lower independent of the sequence context; and iv), the Klenow fragment of DNA polymerase I pauses considerably more at the cross-link of oxaliplatin in all sequence contexts tested. We have also demonstrated that the chirality at the carrier ligand of oxaliplatin can affect its biological effects.
Malina
Jaroslav
J
Institute of Biophysics, Academy of Sciences of the Czech Republic, CZ-61265 Brno, Czech Republic.
Novakova
Olga
O
Vojtiskova
Marie
M
Natile
Giovanni
G
Brabec
Viktor
V
D000970:Antineoplastic Agents / Q000737:chemistry; D020029:Base Pairing; D003432:Cross-Linking Reagents; D018736:DNA Adducts / Q000737:chemistry* / Q000648:ultrastructure*; D006147:Guanine / Q000737:chemistry*; D009690:Nucleic Acid Conformation; D009944:Organoplatinum Compounds / Q000737:chemistry*; D000077150:Oxaliplatin
D000970:Antineoplastic Agents; D003432:Cross-Linking Reagents; D018736:DNA Adducts; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D006147:Guanine
Biochemistry. 2000 Nov 28;39(47):14426-35
11087395
Oncol Rep. 2003 Nov-Dec;10(6):1663-82
14534679
Cancer Res. 1999 Aug 15;59(16):3968-71
10463593
Biophys Chem. 1990 Apr;35(2-3):179-88
2397272
Biochemistry. 1996 Dec 24;35(51):16705-13
8988007
Nature. 1999 Jun 17;399(6737):708-12
10385126
Biochemistry. 1992 Dec 15;31(49):12397-402
1463726
Mutat Res. 2001 Jul 1;478(1-2):1-21
11406166
Biochemistry. 2003 Dec 9;42(48):14197-206
14640687
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7606-11
8755522
Eur J Biochem. 1999 Dec;266(2):392-402
10561579
Biochemistry. 2000 Apr 25;39(16):4575-80
10769112
J Biol Chem. 2001 Jun 22;276(25):22191-9
11303029
Cancer Res. 2004 Jun 1;64(11):3940-8
15173006
Prog Nucleic Acid Res Mol Biol. 2002;71:1-68
12102553
Biophys J. 2000 Apr;78(4):2008-21
10733979
Biochemistry. 2003 Mar 4;42(8):2373-85
12600204
J Mol Biol. 2001 May 18;308(5):823-37
11352575
Biochemistry. 1993 Nov 2;32(43):11676-81
8218235
J Biol Chem. 1996 Jun 28;271(26):15386-92
8663082
Mol Pharmacol. 1998 Nov;54(5):770-7
9804612
Science. 1992 Apr 10;256(5054):234-7
1566071
Cancer Invest. 2001;19(7):756-60
11577818
Biochemistry. 2003 Jan 28;42(3):792-800
12534292
Nucleic Acids Res. 2005;33(18):5819-28
16237123
Prog Nucleic Acid Res Mol Biol. 2001;67:93-130
11525387
J Biol Chem. 2001 Mar 30;276(13):9655-61
11104778
Curr Med Chem. 2003 Feb;10(3):257-66
12570712
Biochemistry. 1990 Jan 30;29(4):1016-24
2340275
Methods Mol Biol. 1997;90:51-79
9407527
J Biol Chem. 2001 Oct 19;276(42):38774-80
11514569
J Mol Recognit. 1990 Feb;3(1):1-25
2191698
Chem Biol. 2002 May;9(5):629-38
12031669
Nucleic Acids Res. 1996 Dec 15;24(24):5062-3
9016685
J Biol Chem. 2002 Dec 13;277(50):48076-86
12226099
Carcinogenesis. 1991 Dec;12(12):2253-7
1747924
Chem Rev. 1999 Sep 8;99(9):2467-98
11749487
Cancer Res. 1994 Jul 1;54(13):3500-5
8012973
J Mol Biol. 2004 Aug 27;341(5):1251-69
15321720
Biochemistry. 1999 Mar 2;38(9):2661-8
10052936
J Biol Chem. 1998 Apr 24;273(17):10355-61
9553091
Nucleic Acids Res. 2003 Nov 15;31(22):6450-60
14602903
Biochem J. 1994 May 15;300 ( Pt 1):165-73
8198530
Biochemistry. 2007 Jun 5;46(22):6477-87
17497831
Nucleic Acids Res. 2001 May 15;29(10):2034-40
11353072
Inorg Chem. 2001 Oct 22;40(22):5596-602
11599959
Biochemistry. 2001 Apr 17;40(15):4769-79
11294645
Arch Biochem Biophys. 2006 Feb 1;446(1):1-10
16405861
Biochemistry. 1999 Jan 12;38(2):715-26
9888812
Nucleic Acids Res. 2002 Jul 1;30(13):2894-8
12087174
Anticancer Drug Des. 1986 Apr;1(2):95-109
3450293
Chem Res Toxicol. 2003 Nov;16(11):1424-32
14615968
Nucleic Acids Res. 2002 Aug 1;30(15):3323-32
12140316
Biochemistry. 2003 Mar 11;42(9):2664-71
12614161
Drug Resist Updat. 2005 Jun;8(3):131-46
15894512
Nature. 1986 Apr 10-16;320(6062):501-6
3960133
Cancer Invest. 1993;11(5):578-89
8402226
Biopolymers. 2005 Mar;77(4):222-9
15666331
J Mol Biol. 2000 Feb 25;296(3):803-12
10677282
J Biol Chem. 2000 May 26;275(21):15789-98
10747955
Cell Mol Life Sci. 2002 Nov;59(11):1914-27
12530522
J Biol Chem. 2000 Apr 28;275(17):13017-25
10777605
Mol Pharmacol. 2000 Nov;58(5):920-7
11040038
Biochemistry. 1999 Aug 24;38(34):11026-39
10460158
J Med Chem. 1990 Aug;33(8):2179-84
2374143
Chemistry. 2005 Sep 5;11(18):5302-10
15997435
Br J Cancer. 1998 Jun;77 Suppl 4:4-7
9647612
Biophys J. 2005 Jun;88(6):4159-69
15805172
Cancer Res. 1998 Aug 15;58(16):3579-85
9721864